The presented PROTAC that is based on KB02 ligand degrades CDK4/6, inhibits the proliferation of triple-negative breast cancer cells (MDA-MB-231), and exhibits therapeutic potential in the xenograft model in vivo. This evidence concerns the gene CDK4 and triple-negative breast carcinoma.